IVF vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a catastrophic 99% decline in share price over the last year. A critical liquidity crisis is evident with a Current Ratio of 0.12 and a Quick Ratio of 0.07, indicating an inability to meet short-term obligations. Negative book value (P/B -0.09) and a massive earnings miss of -158.3% suggest a high risk of insolvency. Despite modest revenue growth, the operational losses and technical collapse make this a high-risk speculative asset.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IVF vs LLY: Head-to-Head Comparison
This page compares INVO Fertility, Inc. (IVF) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.